Clinical Trials Logo

Filter by:
NCT ID: NCT02273167 Completed - Colorectal Cancer Clinical Trials

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.

MORA
Start date: October 2014
Phase: Phase 3
Study type: Interventional

This study evaluates the efficacy, safety and tolerability of NER1006 versus MOVIPREP in adult patients requiring bowel cleansing prior to any procedure that requires a clean bowel, using a 2-Day evening/morning Split-Dosing and 1-Day morning only Split-Dosing regimens. Approximately 810 patients will be randomised with the aim of achieving a minimum of 245 patients in each of the 3 groups.

NCT ID: NCT02272569 Completed - Open Angle Glaucoma Clinical Trials

STARflo European Safety and Efficacy Study

Start date: September 2014
Phase: N/A
Study type: Interventional

Prospective, Non-comparative, Multi-center clinical trial to evaluate the safety and efficacy of the STARflo Glaucoma Implant in patients with refractory open angle glaucoma.

NCT ID: NCT02271867 Completed - Nerve Block Clinical Trials

Thermal QST for Interscale Block Evaluation

Start date: July 2009
Phase: Phase 4
Study type: Interventional

Thermal quantitative sensory testing (QST) is a method to evaluate peripheral nerve blocks in a quantitative way. It assesses the neurosensory effects of local anesthetics, like nerve block intensity, duration, recovery, neurotoxicity, the effect of spread of local anesthetic solutions and the effect and the eventual neurotoxicity of adjuvants. We aimed at investigating, in a quantitative way, the block characteristics of 3 different commonly used local anesthetics on peripheral nerves through the application of thermal QST by measuring changes in sensory detection thresholds. Furthermore, we wanted to evaluate if QST could be of value for measuring gradual changes in block characteristics on the adjacent nerves at distance of the injection site in an US-ISB.

NCT ID: NCT02271841 Completed - Fluid Management Clinical Trials

How Are Changing the Practices After the Introduction of the Pleth Variability Index? A Before/After Survey.

Start date: October 2014
Phase:
Study type: Observational

This study evaluated the practice before and after the introduction of a particular model pulsoxymeter giving, in addition, information on the state of fluid responsiveness of the patient.

NCT ID: NCT02271438 Completed - Healthy Clinical Trials

A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants

Start date: October 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of ibrutinib, to compare the pharmacokinetics of ibrutinib after single oral administration of 840 mg and 1680 mg and to assess the effects of a single dose of ibrutinib on QT/QTc intervals and electrocardiogram (ECG) in healthy adults.

NCT ID: NCT02270944 Completed - Clinical trials for Infections, Streptococcal

Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine

Start date: November 20, 2014
Phase: Phase 2
Study type: Interventional

The purpose of the present study is to assess and compare in healthy non-pregnant women 18 to 40 years of age the safety and immunogenicity of a liquid formulation of Group B Streptococcus (GBS) Trivalent Vaccine (not requiring reconstitution prior to administration), and of the lyophilized formulation of GBS Trivalent Vaccine, administered in non-pregnant and pregnant women in the clinical development program to date.

NCT ID: NCT02269917 Completed - Clinical trials for Human Immunodeficiency Virus Type 1

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Start date: March 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine (FTC)/ tenofovir alafenamide (TAF) (D/C/F/TAF tablet) relative to continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed (human immunodeficiency virus type 1 ribonucleic acid [HIV-1 RNA] concentrations less than [<] 50 copies per milliliter [copies/mL]) HIV-1 infected participants.

NCT ID: NCT02268864 Completed - Clinical trials for Hepatitis C, Chronic

A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants

COMMIT
Start date: January 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of a 12- or 24-week treatment regimen of simeprevir in combination with daclatasvir, as measured by sustain virologic response 12 (SVR12), in treatment-naive, chronic hepatitis C virus (HCV) genotype 1b-infected participants who have advanced fibrosis or compensated cirrhosis (METAVIR F3/F4).

NCT ID: NCT02268552 Completed - Clinical trials for Spinal Muscular Atrophy

An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)

Start date: April 2, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

An open-label, multi-part, first-in-human study of oral branaplam in infants with Type 1 spinal muscular atrophy. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy after 13 weeks; and to estimate the Maximum Tolerated Dose (MTD) of orally administered branaplam; and to identify the dose that is safe for long term use as well as that can provide durable efficacy optimal dosing regimen in patients with Type 1 SMA.

NCT ID: NCT02268526 Completed - HCMV Clinical Trials

Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients

Start date: June 2, 2015
Phase: Phase 2
Study type: Interventional

This study is designed to test if CSJ148 can prevent HCMV replication after stem cell transplantation.